Jubilant Pharmova revenue rises 21% as profit falls 74%
Key highlights
- Jubilant Pharmova reported September-quarter revenue from operations of Rs 2,370 crore, up 21% year on year.
- Jubilant Pharmova’s consolidated profit fell 74% year on year to Rs 31 crore.
- CDMO - Sterile Injectables reported a Rs 4.2 crore segment loss versus a Rs 71 crore profit a year earlier.
- Jubilant Pharmova allotted Rs 800 crore of unsecured NCDs on 5 November 2026.
powered by IRIS

Jubilant Pharmova Limited reported revenue from operations of Rs 2,370 crore for the quarter ended 30 September 2026, up 21% year on year, while consolidated profit for the period fell 74% to Rs 31 crore from Rs 119.9 crore. Total expenses increased 31% to Rs 2,322.7 crore, outpacing income growth.
Know Jubilant Pharmova inside out
Results, valuation, peers and who's buying, in one view.
Why did Jubilant Pharmova’s profit fall despite revenue growth?
Jubilant Pharmova’s profit fell because total expenses rose 31% year on year to Rs 2,322.7 crore in the September 2026 quarter, compared with a 21% rise in total income to Rs 2,384.4 crore. Profit before tax therefore declined 68% to Rs 61.7 crore from Rs 190.3 crore, while tax expense decreased to Rs 30.7 crore from Rs 70.4 crore.
The September 2025 comparison included an exceptional item of Rs 5.8 crore, while the September 2026 quarter recorded no exceptional item. Before exceptional items and tax, profit was Rs 61.7 crore against Rs 196.1 crore a year earlier. That comparison shows the lower result was principally reflected in operating performance rather than arising from the prior-year exceptional charge.
Which Jubilant Pharmova segments drove September-quarter revenue?
Jubilant Pharmova’s Radiopharma segment remained the largest contributor, reporting revenue of Rs 1,009.3 crore for the September 2026 quarter, up from Rs 897.1 crore a year earlier. Contract Development and Manufacturing Organisation (CDMO) - Sterile Injectables delivered the largest absolute increase, with revenue rising Rs 148.1 crore to Rs 559.6 crore.
Generics revenue increased to Rs 274.1 crore from Rs 167 crore, while Allergy Immunotherapy revenue rose to Rs 229.5 crore from Rs 194 crore. Contract Research, Development and Manufacturing Organisation revenue increased Rs 32.3 crore to Rs 344.8 crore. Total segment revenue was Rs 2,417.3 crore, from which Rs 61.8 crore of inter-segment revenue was eliminated; adding Rs 14.5 crore of unallocable corporate revenue produced reported revenue from operations of Rs 2,370 crore.
Where did Jubilant Pharmova’s segment profitability weaken?
Jubilant Pharmova’s CDMO - Sterile Injectables segment reported a loss of Rs 4.2 crore before tax, exceptional items and interest for the September 2026 quarter, compared with a profit of Rs 71 crore a year earlier. The Rs 75.2 crore swing was the largest decline among disclosed operating segments, despite the segment’s 36% revenue growth.
Radiopharma segment profit decreased to Rs 69.8 crore from Rs 95.5 crore, while Allergy Immunotherapy profit declined to Rs 65.7 crore from Rs 74.9 crore. Contract Research, Development and Manufacturing Organisation profit fell to Rs 20 crore from Rs 29 crore. Generics recorded a Rs 5.1 crore profit after a Rs 0.3 crore loss, whereas Proprietary Novel Drugs recorded a Rs 10.2 crore loss compared with a Rs 2.9 crore loss.
Total segment results declined 45% to Rs 146.2 crore from Rs 267.2 crore. Finance costs increased to Rs 58.4 crore from Rs 50.2 crore, and exceptional items and unallocable expenditure, net of unallocable income, were Rs 26.1 crore against Rs 26.7 crore. Those deductions resulted in profit before tax of Rs 61.7 crore, down from Rs 190.3 crore.
Got a follow-up? Ask IRIS
How did Jubilant Pharmova perform in the first half?
Jubilant Pharmova reported revenue from operations of Rs 4,599.4 crore for the half year ended 30 September 2026, a 19% increase from Rs 3,867.1 crore in the corresponding 2025 period. Profit for the period, however, declined 61% to Rs 87.4 crore from Rs 222.4 crore, and profit before tax fell to Rs 148.1 crore from Rs 344.7 crore.
Net cash generated from operating activities was Rs 380.2 crore in the first half, compared with Rs 369 crore a year earlier. Net cash used in investing activities increased to Rs 797.4 crore from Rs 631.2 crore, as purchases of property, plant and equipment and intangible assets, including capital work-in-progress and intangible assets under development, rose to Rs 867.2 crore from Rs 739.7 crore.
Cash and cash equivalents stood at Rs 1,219.8 crore on 30 September 2026, compared with Rs 1,267.1 crore at 31 March 2026. Total assets increased to Rs 16,664.6 crore from Rs 15,522.7 crore, including capital work-in-progress of Rs 3,706.6 crore, up from Rs 2,961.5 crore at the March 2026 year-end.
What changed in Jubilant Pharmova’s borrowings and financing?
Jubilant Pharmova’s total borrowings were Rs 3,892.2 crore at 30 September 2026, comprising Rs 3,433.2 crore of non-current borrowings and Rs 459 crore of current borrowings. This was Rs 672.7 crore above the Rs 3,219.5 crore reported at 31 March 2026, when non-current borrowings were Rs 2,971.7 crore and current borrowings were Rs 247.8 crore.
After the reporting date, Jubilant Pharmova allotted unsecured non-convertible debentures (NCDs) of Rs 800 crore to successful bidders on 5 November 2026. The board had considered and approved the potential private-placement issue on 12 October 2026 of up to 80,000 listed, rated, redeemable and transferable NCDs, each with a face value of Rs 1 lakh, aggregating up to Rs 800 crore.
September-quarter finance costs of Rs 58.4 crore were Rs 8.2 crore above the Rs 50.2 crore recorded a year earlier. In the first half, finance costs rose to Rs 112.6 crore from Rs 99.2 crore, while financing activities generated Rs 371.2 crore of cash, compared with cash outflow of Rs 184.4 crore in the prior-year half.
Conclusion
Jubilant Pharmova delivered higher September-quarter revenue across Radiopharma, Allergy Immunotherapy, CDMO - Sterile Injectables, Contract Research, Development and Manufacturing Organisation, and Generics. However, the 31% increase in expenses, the Sterile Injectables segment’s move to a loss, lower segment results and higher finance costs left quarterly profit at Rs 31 crore, compared with Rs 119.9 crore a year earlier.
The next disclosed financing development is the Rs 800 crore NCD allotment completed on 5 November 2026, after the 30 September reporting date. Subsequent results can show the effect of the Rs 3,892.2 crore borrowing balance, Rs 3,706.6 crore of capital work-in-progress and whether CDMO - Sterile Injectables recovers from its Rs 4.2 crore quarterly loss.


